Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finotonlimab + SCT200 in Advanced ESCC and CRC
NCT04229537Phase 1Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Mar 2020
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of finotonlimab and sct200 in Esophageal Squamous Cell Carcinoma (ESCC) and colorectal cancer (CRC) (3 arms), sponsored by Sinocelltech Group Limited. Primary endpoint: Rate of adverse events at 24 months. Status: unknown.
02
Drugs
finotonlimabsct200
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04229537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229537.